Nuvectis Pharma (NVCT) Projected to Post Quarterly Earnings on Tuesday

Nuvectis Pharma (NASDAQ:NVCT) is expected to announce its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 9:30 AM ET.

Nuvectis Pharma (NASDAQ:NVCT) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.04. On average, analysts expect Nuvectis Pharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nuvectis Pharma Price Performance

Shares of Nuvectis Pharma stock opened at $21.52 on Friday. The business’s 50 day simple moving average is $16.42 and its two-hundred day simple moving average is $11.50. The stock has a market capitalization of $570.93 million, a P/E ratio of -16.43 and a beta of -0.24. Nuvectis Pharma has a one year low of $5.55 and a one year high of $29.27.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. HC Wainwright increased their price objective on Nuvectis Pharma from $13.00 to $39.00 and gave the company a “buy” rating in a research note on Monday, June 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nuvectis Pharma in a research note on Friday, June 5th. Roth Capital upped their price target on shares of Nuvectis Pharma from $20.00 to $33.00 and gave the company a “buy” rating in a report on Monday, July 6th. Wall Street Zen raised shares of Nuvectis Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, UBS Group set a $33.00 price target on shares of Nuvectis Pharma in a report on Monday, July 6th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Nuvectis Pharma has a consensus rating of “Hold” and an average price target of $35.00.

Insider Activity at Nuvectis Pharma

In other Nuvectis Pharma news, major shareholder Marlio Charles Mosseri bought 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The stock was bought at an average price of $18.32 per share, for a total transaction of $916,000.00. Following the completion of the acquisition, the insider directly owned 3,186,576 shares in the company, valued at $58,378,072.32. The trade was a 1.59% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Ron Bentsur purchased 12,500 shares of the company’s stock in a transaction that occurred on Tuesday, June 30th. The stock was acquired at an average cost of $20.00 per share, with a total value of $250,000.00. Following the purchase, the chief executive officer directly owned 3,688,424 shares of the company’s stock, valued at $73,768,480. This trade represents a 0.34% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 28.55% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its position in shares of Nuvectis Pharma by 11.8% in the 4th quarter. Geode Capital Management LLC now owns 364,024 shares of the company’s stock worth $2,749,000 after purchasing an additional 38,291 shares during the period. Bank of America Corp DE increased its position in shares of Nuvectis Pharma by 417.2% during the second quarter. Bank of America Corp DE now owns 8,565 shares of the company’s stock valued at $64,000 after buying an additional 6,909 shares during the period. Vanguard Group Inc. raised its stake in Nuvectis Pharma by 4.8% in the third quarter. Vanguard Group Inc. now owns 698,708 shares of the company’s stock worth $4,206,000 after buying an additional 31,903 shares in the last quarter. State Street Corp raised its stake in Nuvectis Pharma by 13.1% in the fourth quarter. State Street Corp now owns 154,666 shares of the company’s stock worth $1,168,000 after buying an additional 17,950 shares in the last quarter. Finally, Marshall Wace LLP lifted its holdings in Nuvectis Pharma by 63.6% in the second quarter. Marshall Wace LLP now owns 63,613 shares of the company’s stock worth $475,000 after buying an additional 24,739 shares during the period. 96.77% of the stock is owned by hedge funds and other institutional investors.

Nuvectis Pharma Company Profile

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.